Sun Pharmaceutical Industries Ltd.
History
| Year | Detail |
|---|---|
| 1983 | Sun Pharma established the first manufacturing facility for tablets and capsules at Vapi, Gujarat, India. |
| 1988 | launched Monotrate and Angize, our first cardiology products. |
| 1991 | Established our first research center to create a base for strong product and process development. |
| 1995 | Began production at API manufacturing plant in Panoli, Gujarat, India. |
| 1996 | Expanded sales network across 24 countries. |
| 1997 | Acquired Caraco Pharmaceutical Laboratories, U.S. |
| 1999 | Acquired Milmet Labs, Cephalexin, and 7ADCA actives manufacturing site in India. |
| 2004 | Commissioned the first joint venture manufacturing unit in Dhaka, Bangladesh. |
| 2005 | Acquired ICN’s business in Hungary. |
| 2008 | Acquired Chattem Chemicals Inc. |
| 2014 | Sun Pharma and Merck & Co. Inc. entered into a licensing agreement for Tildrakizumab. |
| 2015 | Acquired GSK’s Opiates business in Australia. |
| 2016 | Launched our first branded ophthalmic product, BromSite, in the U.S. |
| 2019 | Acquired Pola Pharma in Japan. |
| 2022 | Acquired Uractiv portfolio from Fiterman Pharma in Romania. |
| 2023 | Acquired Concert Pharmaceuticals. |
BCC Research Beacon 